Filing Flows › Health Care › Scynexis (SCYX)
Scynexis (SCYX) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 10, 2026 · Scynexis (SCYX) Q2 2026 earnings results →
Q2 2026 Revenue down 83% year over year to $235K
Scynexis made $235K in Q2 2026 (-83% Y/Y). Operating margin n/m, net earnings $7.4M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 10, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $235K in Q2 2026, down 83% year over year.
Operating costs exceeded revenue by $7.8M, an operating margin of -3308.5%. Total costs fell 27% while revenue fell 83%. Net earnings were $7.4M. The effective tax rate was 0.0%. Non-operating items added $15.2M, 205% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$14.9M. Non-cash charges added back $568K of share-based compensation. Working capital and other items used $22.9M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 10, 2026 | $235K | -83% | n/m | $7.4M | −$14.9M |
| Q4 2025 | 10-K | Mar 4, 2026 | $18.6M | 19× | 56.4% | $12.3M | $18.4M |
| Q3 2025 | 10-Q | Nov 5, 2025 | $334K | -49% | n/m | −$8.6M | −$8.7M |
| Q2 2025 | 10-Q | Aug 13, 2025 | $1.4M | +85% | -701.0% | −$6.9M | −$7.5M |
| Q1 2025 | 10-Q | May 15, 2025 | $257K | -81% | n/m | −$5.4M | −$7.5M |
| Q4 2024 | 10-K | Mar 12, 2025 | $977K | -83% | -824.3% | −$4.4M | −$9.9M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Scynexis
SCYNEXIS, Inc. is dedicated to advancing innovative solutions for severe rare diseases, with our lead program in the treatment and prevention of difficult-to-treat and drug-resistant fungal infections. We are developing our proprietary antifungal platform “fungerps”, a novel class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have generally shown in vitro and in vivo activity against a broad range of human fungal pathogens such as Candida and Aspergillus genera, including multidrug-resistant strains, as well as Pneumocystis , Coccidioides , Histoplasma and Blastomyces genera and most common mucorales species.
In its own words, from its 10-K, filed Mar 4, 2026.
Scynexis against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -83% against the peers' median +7%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| SCYX Scynexis | Q2 2026 | $235K | -83% | n/m |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Scynexis 10-Q on SEC EDGAR · CIK 1178253 · Pharmaceutical Preparations
13F: who owns SCYX and who is buying
More on SCYX
History
Every quarter: Q2 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results